Summary:
- Cidara Therapeutics, a biotechnology company, has provided a corporate update and reported its financial results for the third quarter of 2024.
- The company's lead product candidate, rezafungin, is currently in late-stage clinical trials for the treatment of invasive fungal infections, a significant unmet medical need.
- Cidara Therapeutics has also made progress in advancing its pipeline of novel antifungal and antibiotic therapies, positioning the company to potentially address the growing challenge of antimicrobial resistance.